HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michihiko Kuwano Selected Research

Everolimus

7/2016Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
1/2014Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michihiko Kuwano Research Topics

Disease

69Neoplasms (Cancer)
01/2022 - 02/2002
18Lung Neoplasms (Lung Cancer)
01/2022 - 04/2004
16Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 04/2004
15Breast Neoplasms (Breast Cancer)
01/2020 - 02/2003
9Carcinoma (Carcinomatosis)
10/2013 - 12/2002
6Hepatocellular Carcinoma (Hepatoma)
07/2016 - 05/2006
5Neoplasm Metastasis (Metastasis)
12/2008 - 01/2003
4Renal Cell Carcinoma (Grawitz Tumor)
01/2014 - 07/2008
4Hypoxia (Hypoxemia)
09/2010 - 07/2003
3Stomach Neoplasms (Stomach Cancer)
05/2013 - 08/2010
3Osteosarcoma (Osteogenic Sarcoma)
09/2010 - 02/2002
3Pancreatic Neoplasms (Pancreatic Cancer)
05/2010 - 06/2006
3Ovarian Neoplasms (Ovarian Cancer)
02/2009 - 11/2002
2Glioblastoma (Glioblastoma Multiforme)
01/2020 - 08/2011
2Colorectal Neoplasms (Colorectal Cancer)
07/2016 - 05/2005
2Carcinogenesis
10/2013 - 07/2003
2Melanoma (Melanoma, Malignant)
06/2009 - 01/2008
2Corneal Neovascularization
09/2007 - 12/2003
2Thyroid Neoplasms (Thyroid Cancer)
04/2006 - 07/2003
2Retinoblastoma (Glioblastoma, Retinal)
12/2005 - 02/2005
2Urinary Bladder Neoplasms (Bladder Cancer)
07/2002 - 04/2002
1Triple Negative Breast Neoplasms
01/2020

Drug/Important Bio-Agent (IBA)

32Proteins (Proteins, Gene)FDA Link
01/2022 - 02/2002
19ErbB Receptors (EGF Receptor)IBA
09/2017 - 04/2004
16Gefitinib (Iressa)FDA Link
03/2015 - 05/2002
15Pharmaceutical PreparationsIBA
01/2022 - 04/2002
12Messenger RNA (mRNA)IBA
01/2014 - 02/2002
11Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2020 - 03/2002
9Erlotinib Hydrochloride (CP 358,774)FDA Link
09/2017 - 12/2006
8Tyrosine Kinase InhibitorsIBA
01/2012 - 05/2002
8Member 1 Subfamily B ATP Binding Cassette TransporterIBA
04/2008 - 04/2002
7Phosphotransferases (Kinase)IBA
05/2019 - 02/2005
7Transcription Factors (Transcription Factor)IBA
05/2019 - 11/2002
5Carrier Proteins (Binding Protein)IBA
01/2020 - 11/2002
5Epidermal Growth Factor (EGF)IBA
04/2011 - 02/2002
5Cisplatin (Platino)FDA LinkGeneric
08/2009 - 08/2002
5Fluorouracil (Carac)FDA LinkGeneric
10/2008 - 12/2006
5Adenosine Triphosphate (ATP)IBA
05/2005 - 11/2002
5multidrug resistance-associated protein 1IBA
05/2005 - 04/2002
4Biomarkers (Surrogate Marker)IBA
12/2018 - 09/2009
4matrigelIBA
01/2014 - 06/2006
4Indicators and Reagents (Reagents)IBA
05/2012 - 07/2002
4Small Interfering RNA (siRNA)IBA
05/2012 - 03/2008
4NF-kappa B (NF-kB)IBA
05/2010 - 09/2007
4TubulinIBA
08/2009 - 06/2007
4Antineoplastic Agents (Antineoplastics)IBA
01/2008 - 04/2002
3ATP-Binding Cassette Transporters (ABC Transporters)IBA
05/2019 - 12/2002
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/2017 - 03/2002
3Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
08/2014 - 12/2003
3CytokinesIBA
08/2013 - 11/2005
3Trastuzumab (Herceptin)FDA Link
05/2013 - 12/2005
3AntibodiesIBA
01/2012 - 09/2004
3CalciumIBA
09/2010 - 11/2003
3Cadherins (E-Cadherin)IBA
02/2010 - 07/2002
3Paclitaxel (Taxol)FDA LinkGeneric
06/2009 - 07/2007
3NickelIBA
12/2008 - 07/2003
3Estrogen Receptor alphaIBA
03/2008 - 05/2006
3Protein Kinase CIBA
01/2008 - 02/2005
3Biological ProductsIBA
11/2007 - 02/2002
2osimertinibIBA
01/2022 - 09/2017
2Estrogen Receptor Modulators (Antiestrogen)IBA
01/2020 - 01/2017
2Growth Factor ReceptorsIBA
05/2019 - 09/2009
2AfatinibIBA
09/2017 - 08/2014
2EverolimusFDA Link
07/2016 - 01/2014
2InterleukinsIBA
01/2014 - 12/2007
2AntioxidantsIBA
10/2013 - 10/2008
2PeroxiredoxinsIBA
10/2013 - 10/2008
2Transcription Factor AP-1 (Transcription Factor AP 1)IBA
08/2013 - 12/2007
2CXC ChemokinesIBA
08/2013 - 05/2010
2Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
08/2013 - 10/2008
2Lapatinib (GW572016)FDA Link
05/2013 - 01/2008
2Angiogenesis InhibitorsIBA
07/2012 - 10/2008
2Threonine (L-Threonine)FDA Link
09/2011 - 05/2010
2Y-Box-Binding Protein 1IBA
08/2011 - 11/2004
2EnzymesIBA
08/2010 - 10/2008
2Thymidine PhosphorylaseIBA
08/2010 - 05/2002
2DNA (Deoxyribonucleic Acid)IBA
07/2010 - 06/2010
2NF-KappaB Inhibitor alphaIBA
05/2010 - 06/2009
2Carboplatin (JM8)FDA LinkGeneric
06/2009 - 07/2007
2taxaneIBA
02/2009 - 06/2007
2Thrombospondin 1IBA
10/2008 - 02/2002
2Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA
10/2008 - 12/2006
2Interferon-alpha2bIBA
10/2008 - 10/2006
2Liposomes (Liposome)IBA
08/2008 - 12/2007
2Multidrug Resistance-Associated ProteinsIBA
04/2008 - 04/2002
2Taxoids (Taxanes)IBA
01/2008 - 06/2007
2Dexamethasone (Maxidex)FDA LinkGeneric
09/2007 - 08/2005
2Complementary DNA (cDNA)IBA
06/2006 - 12/2004
2Mitogen-Activated Protein KinasesIBA
04/2006 - 02/2005
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
04/2006 - 02/2005
2Mitogen-Activated Protein Kinase 3IBA
12/2005 - 04/2004
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
05/2005 - 04/2002
2Semaxinib (SU5416)IBA
05/2002 - 03/2002
170-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA
05/2019
1Androgen Receptors (Androgen Receptor)IBA
05/2019
1Oncogene Proteins (Oncogene Protein)IBA
05/2019
1ChromatinIBA
05/2019

Therapy/Procedure

18Therapeutics
01/2020 - 01/2003
5Drug Therapy (Chemotherapy)
06/2009 - 04/2002
2Aftercare (After-Treatment)
09/2011 - 10/2008